LH

Labcorp Holdings Inc.

$277.74 -6.12 (-2.16%) At close · Jul 8

Market Cap

$22.77B

82,000,000

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$13.95B +7.2%

FY2025

Net Income

$876.5M +17.5%

FY2025

Gross Margin

28.76% +0.9pp

FY2025

Operating Margin

9.92% +1.6pp

FY2025

Diluted EPS

$10.46 +18.3%

FY2025

Operating Cash Flow

$1.64B +3.4%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+5.6%	0.0%	+4.9%	$14.14B	$13.95B	$13.01B	$12.16B	$11.86B	$13.14B	$13.98B	$11.55B	$11.33B	$10.31B	$9.55B	$8.68B	$6.01B	$5.81B	$5.67B	$5.54B	$5B	$4.69B	$4.51B	$4.07B
Cost of Revenue	+6.8%	+1.9%	+5.6%	$10.07B	$9.94B	$9.38B	$8.8B	$8.16B	$8.14B	$9.03B	$8.3B	$8.16B	$7.22B	$6.7B	$5.78B	$3.81B	$3.59B	$3.42B	$3.27B	$2.91B	$2.72B	$2.63B	$2.38B
Gross Profit	+2.7%	-4.1%	+3.3%	$4.08B	$4.01B	$3.62B	$3.36B	$3.71B	$4.99B	$4.95B	$3.25B	$3.18B	$3.09B	$2.85B	$2.9B	$2.2B	$2.22B	$2.25B	$2.27B	$2.1B	$1.97B	$1.87B	$1.69B
Gross Margin	—	—	—	—	28.76%	27.86%	27.67%	31.26%	38.01%	35.43%	28.15%	28.03%	29.99%	29.88%	33.45%	36.65%	38.28%	39.67%	41.04%	41.92%	41.98%	41.59%	41.57%
Selling, General & Administrative	+7.9%	+5.1%	+3.1%	$2.22B	$2.22B	$2.23B	$2.02B	$1.76B	$1.69B	$1.73B	$1.62B	$1.57B	$1.5B	$1.35B	$1.63B	$1.2B	$1.13B	$1.11B	$1.16B	$1.03B	$958.9M	$935.1M	$808.7M
Amortization of Intangibles	+13.1%	+0.3%	+5.5%	$286M	$280M	$256.4M	$219.8M	$193.6M	$229.5M	$275.4M	$243.2M	$231.7M	$216.5M	$179.5M	$164.5M	$76.7M	$81.7M	$86.3M	$85.8M	$72.7M	$62.6M	$57.9M	$54.9M
Depreciation & Amortization	+8.2%	+1.7%	+4.1%	—	$681.1M	$643.5M	$577.3M	$537.2M	$577M	$624.7M	$577.2M	$552.1M	$533.2M	$499.2M	$457.8M	$245.5M	$230.1M	$229.8M	$231.4M	$203.6M	$195.1M	$179.7M	$162.8M
Restructuring Charges	+19.1%	+1.3%	+8.4%	—	—	—	$55.7M	$55.9M	$44.3M	$33M	$33.1M	$52.1M	$76M	$64.7M	$113.9M	$18.9M	$24.9M	—	—	—	$13.5M	$37.9M	$50.6M
Operating Income	-1.2%	-10.8%	+3.3%	$1.44B	$1.38B	$1.09B	$725.6M	$1.44B	$3.05B	$2.45B	$1.33B	$1.33B	$1.31B	$1.27B	$996.8M	$910.4M	$990.9M	$1.02B	$948.4M	$978.8M	$935.9M	$842.9M	$777M
Operating Margin	—	—	—	—	9.92%	8.35%	5.97%	12.11%	23.21%	17.49%	11.51%	11.7%	12.66%	13.3%	11.48%	15.14%	17.06%	18.05%	17.11%	19.56%	19.94%	18.71%	19.1%
EBITDA	+1.5%	-7.6%	+3.6%	—	$2.07B	$1.73B	$1.3B	$1.97B	$3.63B	$3.07B	$1.91B	$1.88B	$1.84B	$1.77B	$1.45B	$1.16B	$1.22B	$1.25B	$1.18B	$1.18B	$1.13B	$1.02B	$939.8M
Interest Expense	+7.6%	+1.6%	-2.0%	$223.2M	$224.1M	$208.3M	$199.6M	$179.8M	$211.8M	$207.4M	$240.7M	$244.2M	$235.1M	$219.1M	$274.9M	$109.5M	$96.5M	$94.5M	$87.5M	$70M	$62.9M	-$72M	-$56.6M
Other Non-Operating Income	—	—	—	-$67.1M	-$55M	$60.2M	$15.5M	-$32.2M	$15.5M	-$226.3M	-$225.3M	-$57.4M	-$227.7M	-$197M	-$270.8M	-$83.7M	-$75.3M	-$79.3M	-$82.3M	-$4.9M	-$3.8M	-$2.1M	-$1.4M
Equity in Earnings of Unconsolidated Entities	—	—	—	-$18.1M	-$13.3M	-$1.4M	-$1.4M	$5.4M	$26.5M	$2.9M	$9.8M	$11.6M	$11.3M	$7.9M	$10M	$14.3M	$16.9M	$21.4M	$9.5M	$10.6M	$13.8M	$14.4M	$77.9M
Income Tax	-0.6%	-19.1%	-2.2%	$209.3M	$229.8M	$212.4M	$188.5M	$233.9M	$690M	$662.1M	$280M	$384.4M	-$155.4M	$360.7M	$287.3M	$314.1M	$340.2M	$359.4M	$333M	$344M	$329M	$307.9M	$325.5M
Net Income	-11.8%	-10.8%	+7.2%	$941.5M	$876.5M	$746M	$418M	$1.28B	$2.38B	$1.56B	$823.8M	$883.7M	$1.23B	$711.8M	$437.6M	$511.2M	$573.8M	$583.1M	$519.7M	$558.2M	$543.3M	$464.5M	$476.8M
Net Margin	—	—	—	—	6.28%	5.73%	3.44%	10.78%	18.1%	11.13%	7.13%	7.8%	11.9%	7.45%	5.04%	8.5%	9.88%	10.28%	9.38%	11.16%	11.57%	10.31%	11.72%
Net Income Attributable to Noncontrolling Interests	-7.2%	+5.9%	+0.9%	$1.2M	$1.2M	$1.1M	$1.2M	$1.5M	$2.2M	$900K	$1.1M	$200K	$5.8M	$1.1M	$1.1M	$1.4M	$1.6M	$1.7M	$13.4M	$13.4M	$12.3M	$13.3M	$0
Comprehensive Income	+4.3%	-8.9%	+21.3%	$1.07B	$1.11B	$543.7M	$613.9M	$977.8M	$2.35B	$1.77B	$914.5M	$754.3M	$1.48B	$416.9M	$161.1M	$434.5M	$570.6M	$607M	$476.7M	$585.2M	$621.5M	$327.8M	$538.1M
EPS (Basic) USD/shares	-9.1%	-5.2%	+10.7%	—	$10.54	$8.89	$4.80	$14.05	$24.60	$13.74	$7.23	$7.48	$10.30	$5.96	$3.81	$5.18	$5.46	$5.23	$4.47	$4.66	$4.35	$3.63	$3.51
EPS (Diluted) USD/shares	-9.2%	-5.2%	+10.8%	—	$10.46	$8.84	$4.77	$13.97	$24.39	$13.64	$7.17	$7.40	$10.15	$5.86	$3.74	$5.08	$5.37	$5.15	$4.39	$4.54	$4.28	$3.57	$3.38
Shares Outstanding (Basic Avg) shares	-3.0%	-6.0%	-3.2%	—	83.2M	83.9M	87.1M	91.1M	96.7M	113.26M	113.96M	118.03M	119.19M	119.31M	115M	98.71M	104.99M	111.39M	116.4M	119.89M	125.01M	127.69M	—
Shares Outstanding (Diluted Avg) shares	-2.9%	-6.0%	-3.3%	—	83.8M	84.4M	87.6M	91.6M	97.5M	114.07M	114.77M	119.43M	120.94M	121.41M	117.1M	100.57M	106.86M	113.37M	118.5M	122.69M	126.99M	130.14M	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.41B in buybacks, $933M in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

EV/EBIT

—

P/E (TTM)

24.60×

Diagnostics & Research median 31.41×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Diagnostics	$10,876,500,000	$10,144,300,000	$9,415,100,000	$9,203,500,000	$10,363,600,000	$9,253,400,000	$7,000,100,000	—
Biopharma Laboratory Services	$3,098,200,000	$2,922,600,000	$2,774,200,000	$2,697,300,000	—	—	—	—
Covance Drug Development	—	—	—	—	—	—	—	$4,313,100,000
Drug Development	—	—	—	—	$2,860,700,000	$4,877,700,000	$4,578,100,000	—
LabCorp Diagnostics	—	—	—	—	—	—	—	$7,030,800,000

By Geography (USD)

Component	2021-12-31	2020-12-31	2019-12-31
North America	$13,093,700,000	$11,525,300,000	—
Europe	$2,050,800,000	$1,512,200,000	—
Other Countries	$976,400,000	$941,000,000	$1,199,700,000
Canada	—	—	$333,300,000
Switzerland	—	—	$532,900,000
United Kingdom	—	—	$507,900,000
United States	—	—	$8,981,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Diagnostics	$1,779,900,000	$1,606,300,000	$1,591,300,000	$2,025,500,000	$3,205,600,000	$2,801,300,000	$1,086,000,000	$1,166,700,000
Biopharma Laboratory Services	$498,500,000	$458,900,000	$396,300,000	$389,100,000	—	—	—	—
Corporate	-$482,200,000	-$670,800,000	-$644,100,000	-$468,800,000	-$404,500,000	-$299,400,000	-$167,300,000	-$144,600,000
Drug Development	—	—	$396,300,000	$389,100,000	$501,000,000	$721,600,000	$411,500,000	$303,600,000

Operating Margin by Segment (%)

Component	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Diagnostics	16.4%	15.8%	16.9%	22%	30.9%	30.3%	15.5%
Biopharma Laboratory Services	16.1%	15.7%	14.3%	14.4%	—	—	—
Drug Development	—	—	—	—	17.5%	14.8%	9%

Key facts CIK 920148 CUSIP 504922105 13F (30d) 46 filings 39 filers Visit website Investor relations